PF-Atlas › Clinical Trials › NCT07234032
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Treprostinil Palmitil Inhalation Powder · Phase 3
Registry ID
NCT07234032
Phase
Phase 3
Status
Not yet recruiting
Drug / intervention
Treprostinil Palmitil Inhalation Powder
Sponsor
Insmed Incorporated
Start
2026-06-05
Enrollment
344
Locations
9
About this trial
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07234032 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.